Physician profile
Martha Bouchard
NPI 1467439893
$7,326.83
in general payments reported to CMS, 2019-2025
35 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,527 · 2020: $381 · 2021: $346 · 2022: $1,068 · 2023: $1,367 · 2024: $915 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,181.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $561.64 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $526.69 | 2021-2025 | Vraylar |
| Exact Sciences Corporation | $521.48 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $459.04 | 2019-2023 | Xarelto |
| Amgen INC. | $415.01 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $394.92 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $347.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $327.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $321.76 | 2019-2024 | Tezspire, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $304.66 | 2021-2025 | |
| Pfizer INC. | $285.44 | 2019-2025 | |
| Amarin Pharma, INC. | $229.34 | 2019-2020 | |
| Celgene Corporation | $186.99 | 2019 | |
| Arbor Pharmaceuticals, INC. | $162.54 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $125.13 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $122.75 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.16 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.97 | 2019-2022 | |
| Ucb, INC. | $108.50 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $91.04 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $71.52 | 2019-2020 | |
| Allergan, INC. | $58.12 | 2019 | |
| Radius Health, INC. | $42.38 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $35.58 | 2023 | Rexulti |
| Avanir Pharmaceuticals, INC. | $31.08 | 2022 | |
| Boston Scientific Corporation | $30.80 | 2022 | |
| Medicomp INC | $24.39 | 2025 | Telepatch Cardiac Monitor |
| Dexcom, INC. | $23.54 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $22.88 | 2019 | |
| Astellas Pharma US INC | $22.30 | 2023 | Veozah |
| Azurity Pharmaceuticals, INC. | $19.25 | 2025 | Horizant |
| Therapeuticsmd, INC. | $16.14 | 2020 | |
| Janssen Biotech, INC. | $15.39 | 2019 | |
| Antares Pharma, INC. | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Bouchard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.